Get started

Biotech

Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
NASDAQ:IBB
by EvanMedeiros
1
Looking at a short on NVTA- Here's whyHello TradingView! I'm Fomo Sapien, a 13 year old trader focusing on stock swing trades. Today, I'd like to share a stock I've been keeping an eye on for a bit- NVTA (Invitae Corp). I found this stock using the Finviz stock screener. I'm looking to short NVTA because of the technical chart- I want to make it clear that I do not and have not done fundamental analysis on this stock beside a bare minimum google search. Anyway, let's talk about the chart. As you can see from the visual, I'm looking to short right around this level (2.08), and I want to short due to the recent consolidation into s/r and ema resistance. If I enter the trade, I will be updating this post with my target(s) and stop loss. Earning are expected on August 9th, with an analyst estimate of a 76 cent loss per share. While this further confirms my short idea, I would plan to exit the trade before earnings regardless- although I am open to a re-entry if the setup doesn't change afterwards. The current price is $2.07 so, following this idea, you could short at the open. Remember I have not entered the trade and this post is more of a heads up- as previously mentioned I'll post an update below if/when I enter the trade. Happy Trading! Fomo
NShort
by fomo_sapien
2
Breakthrough Discovery: AccuTOX Effectively Kills Cancer Cells by @newsfile on 2 Aug 2022, 03:15 Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly due to losses in the ability of a given cell to activate its own cell death via a specific set of proteins known to sense unusual activities. Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this. Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors. The use of AccuTOXTM in combination with multiple immune-checkpoints results in a survival rate between 60% and 100%, based on the pre-clinical tumor models studies in mice. The mode of action of AccuTOXTM approached is a non-biased transcriptomic application and revealed that the compound impairs several crucial pathways including DNA replication, cell division, nuclear integrity, and multiple modifications affecting DNA activity. The accumulation of exhaustive cell repair mechanisms triggered by AccuTOXTM combined to the build-up of misfolded proteins and generation of free radicals induce irreversible DNA damages leading to a general collapse in several cellular pathways resulting in effective cancer cell death. "Defence's breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM. Discovering that AccuTOXTM can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence's pipeline and future potential developments. The AccuTOXTM presents a novel discovery as a platform for targeting multiple cancers. This novel discovery creates significant values and applications to our Antibody Drug Conjugate ("ADC") pipeline. Results are convincing that AccuTOXTM is the perfect potent small molecule to use in the development of our own ADC," says Mr. Plouffe, the CEO of Defence Therapeutics. Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.
CSE:DTCLong
by wealth_bakery
BioNTech showing a solid entryBNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not to say its a sure bet or smart to dump huge amounts into the trade without the stop loss...). Fundamentally, the company has a P/E of 3, no debt, and a huge free cash flow to fund its mrna platforms for a lot of other diseases partnering with some of the largest pharma companies in the world. Yet another variant of covid, upward pressure from the 50and100 day MAs, large portions of the world unvaccinated, and president biden contracting the virus could be potential catalysts for a move. If you're looking for a bio tech exposure this is a stock that seems to be set up well. Good luck to all.
NASDAQ:BNTXLong
by Avatar_Trading
1
Green in the sea of red: Biotech (2)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (link here: ), while more aggressive traders can go with AMEX:XBI (this post) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical The 250 days moving average of AMEX:XBI is pointing downward, and it is currently trading below the 250 days moving average, which confirms the down trend is still effective for AMEX:XBI . Benchmarking with NASDAQ:QQQ (Nasdaq100 index ETF), although both are in similar down trend, AMEX:XBI 20 days moving average has already crossed the 50 days moving average while that of NASDAQ:QQQ still running below, which shows stronger confirmation of the rebound for AMEX:XBI than NASDAQ:QQQ . Here are some important level one should pay attentions to: Downside support 72.55: Jun-30 retest low after breaking 50 days moving average 61.78: May-12 52 weeks low Upside resistance 84.63: Jul-8 high after breaking 50 days moving average 97.19: Apr-5 high before creating new low on May-12 118.23: 2021 May-10 consolidation bottom, which was broken, retested and continued to the downside during 2021 Nov to Dec
AMEX:XBILong
by geoffreyip523
Green in the sea of red: Healthcare (1)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (this post), while more aggressive traders can go with AMEX:XBI (link here: ) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical AMEX:XLV is still outperforming major indexes. Instead of downtrend, AMEX:XLV is still in a consolidation period. AMEX:XLV has been trading in extending box range since Oct-2021, with 1 extension to the upside in Dec-2021, and 1 extension to the downside this year on Jun-13. The more than 8 months of consolidation period has flattened the 250 days moving average, yet not bending it downward (yet?). 20 days and 50 days moving averages have been crossing each other multiple times during the consolidation period, making them less indicative from a technical perspective. Currently AMEX:XLV is trading below 250 days moving average, tested but failed to penetrate the moving average on Jul-8, if it still cannot get above the 250 days moving average in the coming months, the downside pressure will materialize into an actual down trend. In summary, these are the important levels one should pay attention to: Downside support 118.75: Jun-13 new box bottom 109.74: Post covid peak before rallying to the upside Upside resistance 132.04: Jul-8 attempt of breaking 250 days moving average 143.42: Apr-8 new box top
AMEX:XLVLong
by geoffreyip523
$XLV:$KRE: Deflation winners and losersWe're seeing value health care ($XLV) show a lot of relative strength against other sectors as the dollar has been pushing. ($KRE) is often tied to growth when compared to it's bigger brother ($XLF) and eventhough financials do tend to benefit from rising rates, this has been much more of a hard landing and the financial rotation many expect may not come to pass, instead look for $XLV to continue soaking up 2022 when compared to other sectors.
AMEX:XLVLong
by Fox_Technicals
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
NASDAQ:RYTMLong
by BADQOMOCAWGOWLD